Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer's disease and diabetes mellitus
- PMID: 19778613
- DOI: 10.1016/j.nbd.2009.09.008
Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer's disease and diabetes mellitus
Abstract
It has been extensively reported that diabetes mellitus (DM) patients have a higher risk of developing Alzheimer's disease (AD), but a mechanistic connection between both pathologies has not been provided so far. Carbohydrate-derived advanced glycation endproducts (AGEs) have been implicated in the chronic complications of DM and have been reported to play an important role in the pathogenesis of AD. The earliest histopathological manifestation of AD is the apparition of extracellular aggregates of the amyloid beta peptide (Abeta). To investigate possible correlations between AGEs and Abeta aggregates with both pathologies, we have performed an immuhistochemical study in human post-mortem samples of AD, AD with diabetes (ADD), diabetic and nondemented controls. ADD brains showed increased number of Abeta dense plaques and receptor for AGEs (RAGE)-positive and Tau-positive cells, higher AGEs levels and major microglial activation, compared to AD brain. Our results indicate that ADD patients present a significant increase of cell damage through a RAGE-dependent mechanism, suggesting that AGEs may promote the generation of an oxidative stress vicious cycle, which can explain the severe progression of patients with both pathologies.
Similar articles
-
Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism.Exp Neurol. 2001 Sep;171(1):29-45. doi: 10.1006/exnr.2001.7732. Exp Neurol. 2001. PMID: 11520119
-
N epsilon-carboxymethyllysine in brain aging, diabetes mellitus, and Alzheimer's disease.Free Radic Biol Med. 2004 May 15;36(10):1241-7. doi: 10.1016/j.freeradbiomed.2004.02.006. Free Radic Biol Med. 2004. PMID: 15110389
-
RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease.Acta Neuropathol. 2006 Oct;112(4):405-15. doi: 10.1007/s00401-006-0115-3. Epub 2006 Jul 25. Acta Neuropathol. 2006. PMID: 16865397
-
Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease.Neurobiol Aging. 2011 May;32(5):763-77. doi: 10.1016/j.neurobiolaging.2009.04.016. Epub 2009 May 22. Neurobiol Aging. 2011. PMID: 19464758 Review.
-
The relationship between Alzheimer's disease and diabetes: Type 3 diabetes?Altern Med Rev. 2009 Dec;14(4):373-9. Altern Med Rev. 2009. PMID: 20030463 Review.
Cited by
-
Diabetes and Cognitive Impairment.Curr Diab Rep. 2016 Sep;16(9):87. doi: 10.1007/s11892-016-0775-x. Curr Diab Rep. 2016. PMID: 27491830 Free PMC article. Review.
-
Environmental determinants of chronic disease and medical approaches: recognition, avoidance, supportive therapy, and detoxification.J Environ Public Health. 2012;2012:356798. doi: 10.1155/2012/356798. Epub 2012 Jan 19. J Environ Public Health. 2012. PMID: 22315626 Free PMC article. Review.
-
The Effects of Dietary Advanced Glycation End-Products on Neurocognitive and Mental Disorders.Nutrients. 2022 Jun 10;14(12):2421. doi: 10.3390/nu14122421. Nutrients. 2022. PMID: 35745150 Free PMC article. Review.
-
Chaperone Mediated Autophagy in the Crosstalk of Neurodegenerative Diseases and Metabolic Disorders.Front Endocrinol (Lausanne). 2019 Jan 31;9:778. doi: 10.3389/fendo.2018.00778. eCollection 2018. Front Endocrinol (Lausanne). 2019. PMID: 30766511 Free PMC article. Review.
-
Uric acid index is a risk for mild cognitive impairment in type 2 diabetes.Hormones (Athens). 2023 Sep;22(3):425-439. doi: 10.1007/s42000-023-00465-3. Epub 2023 Jul 31. Hormones (Athens). 2023. PMID: 37523135
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical